Saturday 17 October 2026
Export TNON’s income statement to Excel — free account
Tenon Medical, Inc.
TNON Healthcare Medical Devices
Tenon Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.9 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue grew 126.8%, EPS grew 1.88% and free cash flow fell 21.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
2.70
0.21
−7.22%
Follow TNON
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.13 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.01 | 1.78 | 1.78 | 0.70 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.55) | (3.16) | (2.77) | (1.36) | |
P/B ratio |
5.65 | 3.58 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.05 | 0.92 | 0.85 | 0.45 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.59) | (0.34) | (0.35) | (0.20) | |
EV/FCF |
(0.54) | (0.31) | (0.32) | (0.19) | |
Quick Ratio |
1.56 | 1.70 | 0.89 | 0.44 | |
Current Ratio |
2.15 | 2.11 | 1.03 | 0.58 | |
Net Debt/EBITDA |
1.06 | 1.39 | 1.56 | 0.71 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.28 | 0.38 | 0.35 | 0.51 | |
Operating CF/Net income |
1.15 | 0.79 | 0.85 | 0.68 | |
Capex/Depreciation |
(4.41) | (1.17) | (0.17) | (0.18) | |
Interest Coverage |
— | — | (18.64) | (3.94) | |
Research and Development Expense of Revenue |
36.49% | 35.58% | 48.01% | 60.05% | |
Selling, General and Administrative Expense of Revenue |
318.58% | 226.60% | 258.38% | 265.83% | |
Intangible Assets out of Total Assets |
0.28 | 0.27 | 0.22 | 0.29 | |
Share Based Compensation of Revenue |
4.94% | 23.23% | 24.00% | 32.21% | |
Graham Net Nets |
0.10 | 0.15 | (0.41) | (1.83) | |
Graham Number |
224.53 | 0.00 | 60.93 | 121.76 | |
Earnings Yield |
742.68% | (208.82%) | (177.51%) | (393.23%) | |
Free Cash Flow Yield |
(125.13%) | (166.70%) | (150.20%) | (342.69%) | |
Revenue per Share |
4.97 | 7.01 | 4.28 | 3.90 | |
Operating CF per Share |
(16.20) | (10.53) | (9.18) | (8.41) | |
Capex per Share |
(2.71) | (0.91) | (0.17) | (0.52) | |
Free Cash Flow per Share |
(18.91) | (11.44) | (9.36) | (8.93) | |
Cash per Share |
14.58 | 17.78 | 14.29 | 5.11 | |
Shareholders Equity per Share |
20.33 | 23.86 | 5.88 | (5.31) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
20.33 | 23.86 | 5.88 | (5.31) | |
Free Cash Flow |
(4.46) | (2.42) | (3.02) | (2.93) | |
Working Capital |
3.50 | 3.56 | 0.22 | (3.50) | |
Capital Expenditures |
(0.64) | (0.19) | (0.06) | (0.17) | |
Net Current Asset Value |
0.98 | 1.05 | (3.32) | (6.86) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.54 | 0.13 | 0.04 | 0.13 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.09 | 1.28 | 1.43 | 1.36 | |
Average Payables |
0.86 | 0.61 | 0.57 | 0.76 | |
Average Inventory |
0.99 | 0.83 | 0.71 | 0.74 | |
Average Assets |
11.70 | 10.30 | 13.12 | 10.52 | |
Average Common Equity |
3.08 | 2.09 | 2.22 | (0.93) |
Columns are period end dates